Screener
Kymera Therapeutics KYMR Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $124,477 | $357,011 |
| Marketable securities (Note 4) | 566,508 | 491,265 |
| Accounts receivable | 20,000 | — |
| Prepaid expenses and other current assets | 26,280 | 22,938 |
| Total current assets | $737,265 | $871,214 |
| Marketable securities, non-current (Note 4) | 813,901 | 771,158 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's cash & equivalents?
- Kymera Therapeutics (KYMR) reported cash & equivalents of $124.48M in Q2 2026.
- How has Kymera Therapeutics's cash & equivalents changed year-over-year?
- Kymera Therapeutics's cash & equivalents decreased by 62.9% year-over-year, from $335.82M to $124.48M.
- What is the long-term trend for Kymera Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Kymera Therapeutics's cash & equivalents has grown at a 63.0% compound annual growth rate (CAGR), from $31M to $357.01M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Kymera Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude